Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Drugs & Service Coverage Act

Executive Summary

Reps. Jo Ann Emerson (R-Mo.) and Mike Ross (D-Ark.) introduce "Medicare Drug & Service Coverage Act" (HR 3626) Jan. 24 to provide a drug benefit for Medicare beneficiaries funded by a rebate equal to 18% of the average manufacturer price for all "innovator multiple source drugs or single source drugs" covered by the program. The bill contains elements of a proposal by the Pharmacy Benefits All Coalition of pharmacy associations (1"The Pink Sheet" July 2, 2001, p. 7)...

You may also be interested in...



NACDS Interim Medicare Rx Plan: “OneCard” Plus Stop-Loss Coverage

The National Association of Chain Drug Stores is pushing its "OneCard" program as part of a two-prong interim legislative solution to help seniors afford prescription drugs in the absence of a Medicare Rx benefit

Pharmacy Groups Exploring Medicare Rx Fallback Options

The retail pharmacy trade associations hope to reach an agreement on a fallback Medicare drug benefit proposal with a group of pharmaceutical manufacturers over the next month

Pharmacy Coalition Proposes Rebate-Funded Medicare Rx Plan

A prescription drug would be covered by Medicare only if the manufacturer has agreed to provide rebate payments negotiated by HHS under a proposed "Medicare Pharmacy Benefit Act" being circulated on Capitol Hill by a coalition of pharmacy associations.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039223

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel